Breaking News: LTS Lohmann Therapie-Systeme AG Secures $2 Million Funding for Innovative Drug Delivery Systems

In an exciting development for the pharmaceutical industry, LTS Lohmann Therapie-Systeme AG has successfully raised €2,000,000 to further its commitment to innovation in drug delivery systems.

As a distinguished technology partner, LTS is driven by the philosophy of “We CARE. We CREATE.

We DELIVER,” focusing on the development and manufacturing of cutting-edge drug delivery solutions such as Transdermal Patches (TTS), Oral Thin Films (OTF), and wearable devices (OBDS).

This new funding will bolster LTS’s ambitious growth trajectory, enabling the company to enhance its extensive portfolio of over 20 marketed products and advance more than 40 ongoing development projects that address a wide array of disease indications.

Notably, the financing will support the refinement of LTS's core TTS and OTF technologies, while also accelerating the exploration of emerging delivery technologies such as Micro Array Patches (MAP) that facilitate the transdermal administration of large biological molecules.

Additionally, the investment will further expand the capabilities of LTS’s innovative Sorrel™ wearable drug delivery platform, which promises to offer patient-friendly solutions for managing complex medication regimens from the comfort of home.

Established in 1984, with operations spanning four global locations, including Germany, the U.S.

, and Israel, LTS remains dedicated to its mission of delivering reliable, effective drug delivery systems that empower both healthcare providers and patients.

This funding marks a significant milestone in LTS's journey as it continues to lead the way in pharmaceutical innovations that truly make a difference in people’s lives.